Mon­sters, di­nosaurs and su­per­heroes: Why phar­ma is bring­ing char­ac­ters back in­to the ad mix 

Last year
Pharma
Marketing

Mar­ket­ingRx roundup: Study finds gener­ic drugs gain ground, but docs still pre­fer brands; Pfiz­er laud­ed at AACR

Last year
Pharma
Marketing

Brain­Storm out­lines plans for what may be fi­nal at­tempt to bring ALS drug to mar­ket

Last year
R&D
FDA+

Acrivon draws in $130M; Vin­cerx Phar­ma's Ph1 metasta­t­ic tu­mor da­ta

Last year
News Briefing

Up­dat­ed: Steve Paul, Daphne Zo­har re­unite for an­oth­er neu­ro start­up af­ter Karuna suc­cess

Last year
People
Financing

With Ph3 da­ta, Pfiz­er wants to have the ‘first and on­ly’ RSV vac­cine to cov­er adults as young as 18 years old

Last year
R&D

Ex­clu­sive: Dig­i­tal health ven­ture firm De­fine Ven­tures hires in­dus­try vet Frank Williams

Last year
People
Health Tech

Two ex-blue­bird lead­ers launch Nvel­op with $100M to tack­le the biggest prob­lem in gene edit­ing

Last year
Financing

FDA of­fi­cials raise con­cerns with im­munother­a­py overuse for ear­ly-stage can­cer pa­tients: #AACR24

Last year
Pharma
FDA+

Over a year af­ter biosim­i­lars start­ed com­pet­ing, Ab­b­Vie still holds 96% of Hu­mi­ra mar­ket, re­port says

Last year
Pharma

Near­ly half of can­cer drugs grant­ed ac­cel­er­at­ed ap­proval didn’t end up show­ing clin­i­cal ben­e­fit — study

Last year
Pharma
FDA+

Stealth Bio gets FDA ad­comm for pre­vi­ous­ly re­ject­ed ul­tra-rare dis­ease drug

Last year
FDA+

SEC notch­es win in bio­phar­ma 'shad­ow' in­sid­er trad­ing case

Last year
Pharma

Take­da ex­tends rare dis­ease aware­ness cam­paign with pa­tient-in­spired im­agery, sto­ries

Last year
Pharma
Marketing

Ther­mo Fish­er to shrink plas­mid man­u­fac­tur­ing lab in Cal­i­for­nia, lay off 74 work­ers

Last year
Manufacturing

Health tech star­tups raised $2.7B last quar­ter. It's the low­est Q1 to­tal in five years

Last year
Financing
Health Tech

Boehringer In­gel­heim taps Sino Bio­pharm as Chi­nese part­ner for its emerg­ing can­cer pipeline

Last year
Deals
China

As­traZeneca eyes a safer PARP in­hibitor, with near­ly 50% re­sponse in ad­vanced breast can­cer pa­tients: #AACR24

Last year
R&D

No­vo fur­ther boosts ev­i­dence for semaglu­tide’s heart ben­e­fits be­yond weight loss: #ACC24

Last year
R&D

FDA is­sues sec­ond CRL to Su­per­nus for Parkin­son's drug-de­vice com­bo

Last year
FDA+

LIB de­tails Ph3 PC­SK9 in­hibitor da­ta; Eye­n­ovia seeks 's­trate­gic al­ter­na­tives'

Last year
News Briefing

Mer­ck signs small ac­qui­si­tion to make AD­Cs safer

Last year
Startups
Deals

Medicxi backs Chi­nese biotech's next-gen KRAS G12C drug with $40M in­jec­tion

Last year
Financing
China

Al­ny­lam’s RNAi ther­a­py pass­es sec­ond Phase 2 hy­per­ten­sion test, with third un­der­way: #ACC24

Last year
R&D
First page Previous page 174175176177178179180 Next page Last page
A service from the Financial Times